GlassScriptPhysician profile
Natalie Raber
NPI 1366083313
$620.53
in general payments reported to CMS, 2019-2025
19 companies · $179 in 2025
The $179 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $93.52 · 2024: $348 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $620.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $181.79 | 2023-2025 | |
| Daiichi Sankyo INC. | $48.13 | 2024-2025 | Enhertu |
| Janssen Biotech, INC. | $42.46 | 2025 | Darzalex, Talvey, Erleada |
| Abbvie INC. | $40.16 | 2024 | |
| Merck Sharp & Dohme LLC | $35.58 | 2024 | Keytruda |
| Deciphera Pharmaceuticals INC. | $32.03 | 2023-2024 | Qinlock, Tgct |
| Glaxosmithkline, LLC. | $25.44 | 2025 | Zejula, Jemperli |
| Takeda Pharmaceuticals U.S.A., INC. | $24.95 | 2024 | Alunbrig |
| Mirati Therapeutics, INC. | $21.00 | 2024 | Krazati |
| Blueprint Medicines Corporation | $19.73 | 2023 | Ayvakit |
| Genzyme Corporation | $18.07 | 2024 | |
| Genentech USA, INC. | $17.85 | 2025 | Itovebi |
| Lilly USA, LLC | $17.85 | 2024 | Retevmo, Verzenio, Jaypirca |
| Astrazeneca Pharmaceuticals LP | $17.84 | 2024 | Enhertu |
| Celgene Corporation | $16.66 | 2024 | Reblozyl |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $15.77 | 2023 | |
| Incyte Corporation | $15.64 | 2024 | Jakafi |
| Pharmacosmos Therapeutics INC. | $15.17 | 2024 | Monoferric |
| Rigel Pharmaceuticals, INC. | $14.41 | 2024 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Raber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.